Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.

× No keyword cloud information.

11 in total

Review 1. The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?

Authors: M Feldmann; J Bondeson; F M Brennan; B M Foxwell; R N Maini
Journal: Ann Rheum Dis Date: 1999-11 Impact factor: 19.103

2. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.

Authors: F M Brennan; K A Browne; P A Green; J M Jaspar; R N Maini; M Feldmann
Journal: Br J Rheumatol Date: 1997-06

3. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.

Authors: E M Paleolog; M Hunt; M J Elliott; M Feldmann; R N Maini; J N Woody
Journal: Arthritis Rheum Date: 1996-07

4. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

Authors: P Charles; M J Elliott; D Davis; A Potter; J R Kalden; C Antoni; F C Breedveld; J S Smolen; G Eberl; K deWoody; M Feldmann; R N Maini
Journal: J Immunol Date: 1999-08-01 Impact factor: 5.422

5. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

Authors: F M Brennan; D Chantry; A Jackson; R Maini; M Feldmann
Journal: Lancet Date: 1989-07-29 Impact factor: 79.321

6. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors: R O Williams; M Feldmann; R N Maini
Journal: Proc Natl Acad Sci U S A Date: 1992-10-15 Impact factor: 11.205

7. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Authors: M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; P Katsikis; F M Brennan; J Walker; H Bijl; J Ghrayeb
Journal: Arthritis Rheum Date: 1993-12

8. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors: M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal: Lancet Date: 1994-10-22 Impact factor: 79.321

9. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.

Authors: H M Lorenz; C Antoni; T Valerius; R Repp; M Grünke; N Schwerdtner; H Nüsslein; J Woody; J R Kalden; B Manger
Journal: J Immunol Date: 1996-02-15 Impact factor: 5.422

10. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.

Authors: E M Paleolog; S Young; A C Stark; R V McCloskey; M Feldmann; R N Maini
Journal: Arthritis Rheum Date: 1998-07

17 in total

Review 1. Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors: N Fathy; D E Furst
Journal: Springer Semin Immunopathol Date: 2001

Review 2. Granulomatous diseases.

Authors: P Kaye
Journal: Int J Exp Pathol Date: 2000-10 Impact factor: 1.925

Review 3. Group A beta-hemolytic streptococcal glossal necrotizing myositis--case report and review.

Authors: Robert H Baevsky; Jay T Ishida; Stephen A Lieberman
Journal: MedGenMed Date: 2005-06-30

4. Lentiviral small hairpin RNA knockdown of macrophage inflammatory protein-1γ ameliorates experimentally induced osteoarthritis in mice.

Authors: Po-Chuan Shen; Chia-Sing Lu; Ai-Li Shiau; Che-Hsin Lee; I-Ming Jou; Jeng-Long Hsieh
Journal: Hum Gene Ther Date: 2013-10 Impact factor: 5.695

Review 5. Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.

Authors: B M Foxwell; J Bondeson; F Brennan; M Feldmann
Journal: Ann Rheum Dis Date: 2000-11 Impact factor: 19.103

6. Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects.

Authors: F P Conte; O Menezes-de-Lima; W A Verri; F Q Cunha; C Penido; M G Henriques
Journal: Br J Pharmacol Date: 2010-10 Impact factor: 8.739

Review 7. Infliximab: a review of its use in the management of rheumatoid arthritis.

Authors: A Markham; H M Lamb
Journal: Drugs Date: 2000-06 Impact factor: 9.546

8. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography.

Authors: E Naredo; G Bonilla; F Gamero; J Uson; L Carmona; A Laffon
Journal: Ann Rheum Dis Date: 2005-03 Impact factor: 19.103

9. Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.

Authors: Annamaria Iagnocco; Chiara Perella; Esperanza Naredo; Gary Meenagh; Fulvia Ceccarelli; Emanuela Tripodo; Stefania Basili; Guido Valesini
Journal: Clin Rheumatol Date: 2007-10-19 Impact factor: 2.980

10. The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.

Authors: Marina Stolina; Brad Bolon; Scot Middleton; Denise Dwyer; Heather Brown; Diane Duryea; Li Zhu; Alison Rohner; James Pretorius; Paul Kostenuik; Ulrich Feige; Debra Zack
Journal: J Clin Immunol Date: 2008-08-26 Impact factor: 8.317